Abstract
We evaluated the in vitro activity of cefiderocol in combination with either taniborbactam or xeruborbactam against cefiderocol-resistant, bla NDM-positive Pseudomonas aeruginosa clinical isolates from Vietnam and Nigeria. Taniborbactam restored cefiderocol susceptibility in most isolates (20/21, 95.2%), while xeruborbactam had no effect. Resistance was reversed by dipicolinic acid, which confirmed New-Delhi Metallo-β-Lactamase (NDM-mediated) resistance. One isolate that was unresponsive to taniborbactam carried multiple copies of bla NDM-1. These findings highlight the species-specific limitations of xeruborbactam in P. aeruginosa.
| Original language | English |
|---|---|
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 69 |
| Issue number | 11 |
| Pages (from-to) | e0085725 |
| ISSN | 0066-4804 |
| DOIs | |
| Publication status | Published - 05.11.2025 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
-
SDG 6 Clean Water and Sanitation
Fingerprint
Dive into the research topics of 'Efficacy of cefiderocol in combination with xeruborbactam versus taniborbactam against cefiderocol-resistant NDM-producing Pseudomonas aeruginosa.'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver